Confirmed: the 100% tariff expanded today to every patented-branded-drug company not named in Annex II or III, per CBP's September 28 implementation guidance (CSMS #70054007). The 17 Annex III companies have paid it since July 31. EU branded pharma stays capped at 15% by the trade deal regardless. Model your pharma import costs →
The 100% tariff on patented branded drugs — the single highest product-specific rate in the current US trade book — is now fully in force across the industry. Proclamation 11020 (signed April 2, 2026) phased the tariff in by company: the **17 large pharmaceutical companies named in the proclamation's Annex III hit the 100% rate on July 31, 2026** (120 days after signing); every other company not separately named **joined them on September 29, 2026** (180 days after signing), confirmed by CBP's September 28 implementation guidance (CSMS #70054007). Companies that negotiated a Commerce onshoring agreement — the application window closed June 12, 2026 — pay 20% instead of 100%; companies that also hold a most-favored-nation drug-pricing deal with HHS (13 companies, per Annex II) pay 0% until January 20, 2029. Separately, the July 1 EU-US trade deal caps **EU branded pharma at 15%**, shielding Ireland (~$50B in US-bound branded drugs) and Germany (~$14B) regardless of annex status. Switzerland ($23B) is not an EU member and stays fully exposed to the company-based rate. Generics remain outside the threat — and EU generics went MFN-only (typically 0%) on September 1. Here's what's now in force, and how it plays out country by country.
What's In Force Now (Fully Phased In as of September 29, 2026)
The 100% Section 232 tariff on patented branded drugs and APIs is now fully phased in. The 17 large companies named in Proclamation 11020's Annex III have paid the 100% rate since July 31, 2026 — 120 days after the April 2 signing. Every other company not named in Annex II or III joined them on September 29, 2026 (180 days after signing) — that was the real date for most mid-size and smaller manufacturers, not July 31, and CBP confirmed it in September 28 implementation guidance (CSMS #70054007). EU-origin pharmaceuticals continue to pay the trade deal's 15% all-inclusive ceiling instead (since July 1, 2026 — the ceiling applies in lieu of Section 232 for pharma, regardless of a company's annex status). MFN base on chapter 30 is 0% under the WTO Pharmaceutical Tariff Elimination Agreement. Two relief paths remain: companies with a Commerce-approved onshoring agreement (application window closed June 12, 2026) pay 20% instead of 100%; the 13 companies in Annex II that separately signed most-favored-nation pricing agreements with HHS pay 0% until January 20, 2029. The administration's stated rationale is reshoring — and the pressure track is widening: on June 18, 2026, USTR opened a Section 301 investigation against Germany over persistent underpayment for innovative pharmaceutical products.
Why Pharma Has Been Duty-Free Since 1995
The WTO Pharmaceutical Tariff Elimination Agreement of 1995 — signed by the US, EU, Japan, Switzerland, and others — eliminated MFN duty on roughly 7,000 pharmaceutical products in chapter 30. The Section 122 layer added 10% in February 2026 — the first US import duty on pharma in 30+ years. A 100% Section 232 layer on top would be the biggest reversal since the agreement was signed. The legal authority works because Section 232 supersedes the WTO commitment when invoked on national security grounds.
Advertisement
Worked Example: $1M Branded Drug Shipment from Ireland vs. Switzerland
A $1,000,000 CIF shipment of a patented branded drug from a Pfizer facility in Cork, Ireland, classified under HTS 3004.90 (other medicaments, retail-packaged). MFN: 0%. Since July 1, 2026, the EU deal's 15% ceiling governs: $150,000. MPF capped at $634.62 per entry, HMF at 0.125% = $1,250. Total duty: roughly $151,885 — effective rate about 15.2%, and capped there regardless of the company's Annex II/III status. Now run the identical $1M shipment from a Roche facility in Basel, Switzerland — not an EU member, not covered by the deal. If the manufacturer has a Commerce onshoring agreement: 20% = $200,000. If it's named in Annex III: 100% since July 31, 2026 = $1,000,000 of duty on a $1M shipment. If it's not named in Annex II or III at all, that same 100% exposure has applied since September 29, 2026. The Ireland-vs-Switzerland delta under the worst case is roughly $850,000 per container on identical molecules — the deal turned EU origin into pharma's most valuable sourcing attribute.
Generics, APIs, and Medical Devices Stay Different
Generic drugs pay the base reciprocal forced-labor tariff — 10% or 12.5% depending on origin (India, the largest generic source, is in the 12.5% tier) — on top of 0% MFN. The 100% rate is patent-specific. Active pharmaceutical ingredients (APIs, HTS 2941 and 2942) pay the same base reciprocal forced-labor tariff plus 0% MFN — same as generics. Medical devices (chapter 90) are excluded from chapter 30 and have their own MFN structure: most diagnostic equipment is 0%, surgical instruments 0%, dental equipment 0-2%. So the 100% threat does not hit Indian generic exporters (Cipla, Dr. Reddy's, Sun Pharma), it does not hit Chinese API producers (Section 301's separate 25% Chinese layer applies, putting Chinese APIs at 37.5% combined — 12.5% base + 25% Section 301), and it does not hit medical device makers in Ireland or Germany. The 100% rate is a precision instrument aimed at branded patent-holding manufacturers — primarily US firms producing offshore to capture Irish and Swiss tax treatment.
Country Exposure: The EU Deal Redrew the Map
Ireland ships roughly $50B in pharma to the US annually, primarily branded patented drugs from Pfizer, Eli Lilly, AbbVie, Merck, and Johnson & Johnson facilities operating under Ireland's 12.5% corporate tax rate — and as of July 1, 2026, all of it is capped at 15% by the EU-US trade deal. Germany's ~$14B (Bayer, Boehringer Ingelheim) gets the same 15% cap, though Germany now faces a separate USTR Section 301 investigation (opened June 18, 2026) over underpayment for innovative drugs. Switzerland is the exposed one: ~$23B dominated by Roche and Novartis, not an EU member, not covered by the deal — Swiss branded pharma faces 20% with a Commerce onshoring agreement or 100% without one, a rate now fully in force for every manufacturer (since July 31 for those named in Annex III, since September 29 for everyone else). India is the largest source of generic dose volume (~$9B, almost all generic) and stays outside the branded tariff entirely. China runs ~$2.5B mostly in APIs (35% effective with Section 301). The bottom line: the 100% tariff is now effectively a Switzerland-and-everyone-else problem, not an Ireland problem.
Three Dates That Mattered — All Now Behind Us
Three dates drove this rollout and all three have now passed. The onshoring negotiation window — Commerce's application process for companies wanting the 20% rate — closed June 12, 2026. July 31, 2026 was the day the 100% tariff took effect for the 17 companies named in the proclamation's Annex III (120 days after the April 2 signing). September 29, 2026 (180 days after signing) was the later date for every other company not named in Annex II or III — confirmed as implemented by CBP's September 28 guidance (CSMS #70054007), which also notes that from July 31 through September 28, non-Annex-III importers still had to report the Chapter 99 provision (9903.04.61) even though duties weren't yet due in that window. With both effective dates now behind us, the 100% rate applies industry-wide except for the two relief paths: an onshoring agreement (20%) or an Annex II MFN pricing deal (0% until January 20, 2029). EU-origin branded pharma is capped at 15% by the trade deal regardless of annex status; EU generics, APIs, and chemical precursors went MFN-only (typically 0%) on September 1; and generics from any origin stay outside the branded threat entirely.
What This Does to US Drug Prices
A 100% tariff flows into US patient prices — eventually. Drug companies pay duty at the port (the importer is usually the US sales sub of the multinational), and the duty becomes a cost of goods. On patented drugs with no generic competition, pricing power is high — 70-90% pass-through to commercial insurers and patient out-of-pocket over 12-24 months. Medicare Part D and Medicaid pricing is partly constrained by IRA negotiations, but rebates work off list price, and list prices reset upward to absorb the duty. US branded drug spending runs about $400B a year. The EU deal's 15% cap sharply reduces the worst case — roughly two-thirds of US-bound branded pharma value (Ireland, Germany, and other EU origins) is now capped at 15% rather than exposed to 100% — leaving the heaviest price pressure concentrated in Swiss-origin and other non-EU branded product without an onshoring agreement. The administration's counter is reshoring — but reshoring a major facility runs 5-7 years and tens of billions in capex. Duty has been hitting Annex III companies since July 31, 2026 and every other patented-branded-drug company since September 29, 2026; reshoring offset arrives 2031 at the earliest.
What Importers Should Do Now
Step 1: Sort every pharma SKU by origin and by manufacturer — EU branded product is capped at 15% by the trade deal regardless; non-EU branded product (Switzerland foremost) now carries live exposure with no company left in a grace period. Step 2: Confirm whether your supplier holds an onshoring agreement (20%) or an Annex II MFN pricing deal (0% until 2029) — absent one of those, every patented-branded-drug company now pays the 100% rate, whether it was named in Annex III (since July 31) or not (since September 29). Step 3: For non-EU branded imports without a confirmed exemption, model landed cost at 100% (or 20% with an onshoring agreement) against Q4 2026 forecasts. Step 4: For EU generic and API lines, model the September 1 MFN-only shift already in effect — near-0% duty makes delaying non-urgent shipments worth real money. Step 5: For API buyers, Chinese APIs remain at 37.5% effective with Section 301 and carry separate escalation risk. Step 6: Confirm patent status on every imported SKU — a branded-vs-generic indicator drives rate treatment on entries now that the tariff is fully live across the industry.
Key Takeaway
Trump's pharma tariff structure has three tiers: EU branded pharma capped at 15% by the trade deal effective July 1 regardless of manufacturer; non-EU branded drugs facing 20% (with an onshoring agreement) or 100% (without one — live since July 31 for the 17 Annex III companies, and since September 29 for every other company); and generics outside the tariff entirely, with EU generics going MFN-only on September 1. Ireland and Germany are shielded; Switzerland takes the hardest exposure; India's generics business stays insulated. The 100% rate is now fully phased in across the industry, so pharma importers without a confirmed onshoring agreement or Annex II exemption should assume it applies to every non-EU branded SKU they import.
Calculate Your Import Duty
Get an instant estimate for your specific product, country, and shipment value.
Open the US Import Duty CalculatorAdvertisement